Modality
mAb
MOA
MALT1i
Target
MET
Pathway
NF-κB
SchizophreniaNBALL
Development Pipeline
Preclinical
~May 2017
→ ~Aug 2018
Phase 1
~Nov 2018
→ ~Feb 2020
Phase 2
~May 2020
→ ~Aug 2021
Phase 3
~Nov 2021
→ ~Feb 2023
NDA/BLA
May 2023
→ Jul 2029
NDA/BLACurrent
NCT05513828
962 pts·NB
2025-06→2029-07·Terminated
NCT04606982
1,217 pts·NB
2023-05→TBD·Terminated
2,179 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-07-073.3y awayPh3 Readout· NB
Trial Timeline
Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
NDA/BLA
Termina…
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2029-07-07 · 3.3y away
NB
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05513828 | NDA/BLA | NB | Terminated | 962 | HAM-D |
| NCT04606982 | NDA/BLA | NB | Terminated | 1217 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| ITC-6153 | Intra-Cellular | Phase 3 | KRASG12C | |
| Gelisertib | Samsung Biologics | Approved | IL-23 |